Abstract
Cancer drug resistance was long believed to arise from pre-existing mutations that allow rare tumour cells to survive. Increasing evidence suggests a non-genetic component provides reversible advantages to a small, rare subpopulation of tolerant cells. Examining tolerant cell populations for markers of cellular plasticity could tell us whether these survival mechanisms already exist within tolerant cells or whether they can be induced using targeted therapies.